Studies Comparing Immunogenicity of Biosimilars and their Reference Products for the Treatment of Plaque Psoriasis.
Published: 12 January 2026| Version 1 | DOI: 10.17632/xfb9wb8bmp.1
Contributors:
, Description
Studies comparing immunogenicity of biosimilars and their reference products that are used for the treatment of plaque psoriasis. (*) indicates when a study reported EU-reference product. ADA percentages indicate the number of patients who developed anti-drug antibodies. NAb percentages indicate the percentage of total patients who developed neutralizing antibodies.
Files
Categories
Pharmacology, Biologic Therapy, Psoriasis